Clinical Trials
134 trialsDAREONᵀᴹ-8
Boehringer Ingelheim
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
Hoffmann-La Roche
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
PanTumor-101
GlaxoSmithKline
Liver-NET1
University Hospital, Grenoble
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
National Cancer Institute (NCI)
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech, Inc.
DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
Washington University School of Medicine
A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma
Incyte Corporation
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
M.D. Anderson Cancer Center
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
RayzeBio, Inc.
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Bionoxx Inc.
LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer
City of Hope Medical Center
STEALTH-001
KaliVir Immunotherapeutics
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
Bionoxx Inc.
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Zai Lab (Hong Kong), Ltd.
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Memorial Sloan Kettering Cancer Center
TIARA
Yale University
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
Imugene Limited
Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
The Methodist Hospital Research Institute
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Neoadjuvant Atezolizumab in Cutaneous Melanoma
The Methodist Hospital Research Institute
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
Hoffmann-La Roche
AflacST2301
Emory University
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
SBRT With Atezo/Bev for HCC
Abramson Cancer Center at Penn Medicine
All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
Rutgers, The State University of New Jersey
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
Trial of INI-4001 in Patients With Advanced Solid Tumours
Inimmune Corporation
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
InxMed (Shanghai) Co., Ltd.
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
Memorial Sloan Kettering Cancer Center
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
LB-LR1109
LG Chem
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
National Cancer Institute (NCI)
EIK1001
Eikon Therapeutics
Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
University of California, Davis
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
University of California, Irvine
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
National Cancer Institute (NCI)